{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:19:14Z","timestamp":1782785954424,"version":"3.54.5"},"reference-count":32,"publisher":"SAGE Publications","issue":"13","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"The Japanese Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["16K09901"],"award-info":[{"award-number":["16K09901"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Autoantibodies (auto Abs) and inflammatory mediators (IMs) in cerebrospinal fluid (CSF) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). It is suggested that anti-\n                      <jats:italic>N<\/jats:italic>\n                      -methyl D-aspartate receptor NR2 subunit (NR2) Ab can develop NP manifestation after blood\u2013brain barrier (BBB) abruption. We also reported the association between NPSLE and CSF anti-U1RNP Ab. In the present study, combined effects of CSF anti-NR2 and anti-U1RNP Abs on IMs in patients with NPSLE were examined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CSF samples were collected from 69 patients with NPSLE and 13 non-NPSLE controls. CSF anti-NR2 and anti-U1RNP Abs were determined using ELISA. Levels of IL-6, IL-8, and monokine induced by IFN-\u03b3 (MIG) in CSF were measured by quantitative multiplex cytokine analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CSF IL-6 levels were higher in CSF anti-NR2-positive than in CSF anti-NR2-negative patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) and non-NPSLE controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015) and were positively correlated with anti-NR2 titer (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.42). CSF IL-8 levels were higher in CSF anti-U1RNP-positive than in CSF anti-U1RNP-negative patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). CSF MIG levels were more elevated in CSF anti-NR2-positive (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043) and anti-U1RNP-positive patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029) than in non-NPSLE controls. Additionally, in double positive (DP; both anti-NR2 and U1RNP Ab positive) group, CSF IL-6 and MIG levels were significantly higher than in the double negative (DN; both anti-NR2 and U1RNP Ab negative) group. However, combined effect of both Abs on IM elevation and clinical manifestation was not clear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CSF anti-NR2 and anti-U1RNP Abs have different effects on the elevation of CSF IM levels in patients with NPSLE. Additional effect of anti-U1RNP Abs on anti-NR2 Ab-mediated NP manifestation, however, was not recognized in our study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0961203320954918","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T01:08:01Z","timestamp":1599181681000},"page":"1673-1682","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of anti-NR2 and U1RNP antibodies with neurotoxic inflammatory mediators in cerebrospinal fluid from patients with neuropsychiatric systemic lupus erythematosus"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3146-7140","authenticated-orcid":false,"given":"Seiko","family":"Kondo-Ishikawa","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"Rheumatology, National Hospital Organization Utano Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Ishigooka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of the Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of the Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyo","family":"Mimori","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.5.1367"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380823"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.15"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148502"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.10.003"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071285"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1101-1189"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.011"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23399"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar4518"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27700"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314522337"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0624-y"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22451"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316629556"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.148"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.2.1192"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/268436"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.01.010"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00484"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.37745"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu501oa"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2004.00976.x"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003347"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker272"},{"key":"e_1_3_4_30_2","first-page":"1003","article-title":"Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus","volume":"36","author":"Hirohata S","year":"2018","unstructured":"Hirohata S, Sakuma Y, Matsueda Y, Arinuma Y, Yanagida T. Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 2018; 36: 1003\u20131007.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1226-8"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314546020"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1123345"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203320954918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0961203320954918","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203320954918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:22:56Z","timestamp":1777677776000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0961203320954918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1177\/0961203320954918"],"URL":"https:\/\/doi.org\/10.1177\/0961203320954918","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}